RAMM Pharma Corp.

RAMM

CA75150G1046

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 14:47:16 2024-06-10 EDT			5-day change	1st Jan Change
0.02 ^CAD	0.00%		0.00%	-63.64%

03-29	RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
03-19	RAMM Pharma Corp. cancelled the transaction announced on September 5, 2023	CI

Canapar Corp. announced that it has received CAD 6.427 million in funding from RAMM Pharma Corp.

January 30, 2021

In January 2021, Canapar Corp. closed the transaction.

Latest news about RAMM Pharma Corp.

RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-29	CI
RAMM Pharma Corp. cancelled the transaction announced on September 5, 2023	03-18	CI
RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	02-28	CI
RAMM Pharma Corp. Announced Corporate Update; Looking At Legal Options Around Private Placement; Rose 28% on Friday	11-20	MT
RAMM Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-28	CI
RAMM Pharma Drops 30% As Says Seeking Advice After CSE Required Shareholder Approval For Private Placement	23-09-28	MT
RAMM Pharma Seeking Advice After CSE Required Shareholder Approval For Private Placement	23-09-28	MT
RAMM Pharma Corp. announces an Equity Buyback for 5% of its issued share capital.	23-09-05	CI
RAMM Pharma Corp. announced that it expects to receive CAD 1 million in funding	23-09-04	CI
RAMM Pharma Corp. authorizes a Buyback Plan.	23-09-04	CI
RAMM Pharma Corp.'s Equity Buyback announced on August 17, 2022, has expired.	23-08-20	CI
RAMM Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-27	CI
RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-04-03	CI
RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2022	23-02-27	CI
RAMM Pharma Names Interim CFO	22-12-09	MT
RAMM Pharma Corp. Announces Chief Financial Officer Changes	22-12-09	CI
RAMM Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-09-29	CI
The Green Organic Dutchman Closes Sale of HemPoland Subsidiary	22-09-06	MT
RAMM Pharma Says to Start Normal Course Issuer Bid	22-08-17	MT
RAMM Pharma Corp. announces an Equity Buyback for 5% of its issued share capital.	22-08-17	CI
RAMM Pharma Corp. authorizes a Buyback Plan.	22-08-16	CI
RAMM Pharma Corp.'s Equity Buyback announced on July 6, 2021 has expired.	22-07-10	CI
RAMM Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	22-06-28	CI
RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2022	22-04-01	CI
RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2021	22-03-22	CI

RAMM Pharma Corp. is a Canada-based company that is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a diversified international production and sales platform. The Company operates a pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale and/or use in several Latin American countries. The Company has a pipeline of products, including registered hemp-based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at its formulation facility in Montevideo, Uruguay. The Company's brands include NettaPet and NettaVet. Its subsidiaries include Canapar Corp., HemPoland S.p. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RAMM PHARMA CORP.	-63.64%	1.74M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B